Staidson (Beijing) BioPharmaceuticals Co 300204.SZ · CNY

Its shares trade on Shenzhen under the ticker 300204.SZ. It has been listed since 15 April 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥220.2m and a net loss of CN¥77.8m. At that date it held total assets of CN¥1.27bn and shareholders' equity of CN¥820.8m.

Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research and development, production, and marketing of innovative drugs with independent intellectual property rights. The company is headquartered in Beijing, Beijing. The company went IPO on 2011-04-15. The Company’s products include mouse nerve growth factor for injection, which are applied in the neuroprotection and treatment of nerve injuries, as well as polyethylene glycol electrolyte powders, which are applied in the bowel cleansing and treatment of constipation. The firm mainly distributes its products in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Zhiwen ZhouChairman of the Board, since 2022CN¥429,500
• Mr. Shicheng LiChief Financial Officer, Deputy General Manager
• Mr. Chao WangFinance Director, General Manager
• Ms. Lei ZhangChief Human Resources Officer
• Mr. Maorong YuDeputy General Manager, Secretary of the Board
• Ms. Xuelian BaiGeneral Manager - Clinical Research Center
• Mr. Lei TianChief Production Center Officer
• Mr. Jingfeng WangGeneral Manager - Marketing and Self Operated Business
• Ms. Xiaoyan WangDirector
• Mr. Lianchun YangDirector
• Mr. Hongshan ZhangDirector, since 2025CN¥420,900
• Mr. Rongqin ZhangDirector, since 2004CN¥522,200

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.